Protective efficacy in sheep of adenovirus-vectored vaccines against bluetongue virus is associated with specific T cell responses

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Martín, Verónica ^a   Pascual, Elena ^a   Avia, Miguel ^a   Peña, Lourdes ^a   Valcárcel, Félix ^a   Sevilla, Noemí ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLUETONGUE VIRUS VACCINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 3; PROTEIN VP2; PROTEIN VP7; UNCLASSIFIED DRUG; VIRUS VACCINE; CAPSID PROTEIN; RECOMBINANT VACCINE; S10 PROTEIN, BLUETONGUE VIRUS; VIRAL PROTEIN; VP2 PROTEIN, BLUETONGUE VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLUETONGUE ORBIVIRUS; BLUETONGUE VIRUS INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN ADENOVIRUS 5; HUMORAL IMMUNITY; IMMUNOMODULATION; INFECTION CONTROL; MOUSE; NATURAL HOST; NONHUMAN; PROTEIN EXPRESSION; SHEEP; VACCINATION; VIREMIA; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION; ADENOVIRIDAE; ANIMAL; BLUETONGUE; C57BL MOUSE; CHLOROCEBUS AETHIOPS; GENETICS; HAMSTER; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; T LYMPHOCYTE; VERO CELL LINE;

ADENOVIRIDAE; ANIMALS; BLUETONGUE; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; CRICETINAE; FEMALE; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; SHEEP; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 84957058967     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143273     Document Type: Article

References (52)

1. Mellor PS, Baylis M, Mertens PP. Bluetongue: London: Academic Press; 2009.
2. Roy P. Bluetongue virus proteins and particles and their role in virus entry, assembly, and release. Adv Virus Res. 2005; 64:69-123. Epub 2005/09/06. doi: 10.1016/S0065-3527(05)64004-3 PMID: 16139593.
3. Ratinier M, Caporale M, Golder M, Franzoni G, Allan K, Nunes SF, et al. Identification and characterization of a novel non-structural protein of bluetongue virus. PLoS pathogens. 2011; 7(12):e1002477. Epub 2012/01/14. doi: 10.1371/journal.ppat.1002477 PMID: 22241985; PubMed Central PMCID: PMC3248566.
4. Wilson WC, Ma HC, Venter EH, van Djik AA, Seal BS, Mecham JO. Phylogenetic relationships of bluetongue viruses based on gene S7. Virus research. 2000; 67(2):141-51. Epub 2000/06/27. PMID: 10867193.
5. Grimes JM, Burroughs JN, Gouet P, Diprose JM, Malby R, Zientara S, et al. The atomic structure of the bluetongue virus core. Nature. 1998; 395(6701):470-8. Epub 1998/10/17. doi: 10.1038/26694 PMID: 9774103.
6. Mertens PP, Burroughs JN, Anderson J. Purification and properties of virus particles, infectious subviral particles, and cores of bluetongue virus serotypes 1 and 4. Virology. 1987; 157(2):375-86. Epub 1987/04/01. PMID: 3029978.
7. Maan S, Maan NS, Samuel AR, Rao S, Attoui H, Mertens PP. Analysis and phylogenetic comparisons of full-length VP2 genes of the 24 bluetongue virus serotypes. The Journal of general virology. 2007; 88 (Pt 2):621-30. Epub 2007/01/26. doi: 10.1099/vir.0.82456-0 PMID: 17251581.
8. Maan NS, Maan S, Belaganahalli MN, Ostlund EN, Johnson DJ, Nomikou K, et al. Identification and differentiation of the twenty six bluetongue virus serotypes by RT-PCR amplification of the serotype-specific genome segment 2. PloS one. 2012; 7(2):e32601. Epub 2012/03/06. doi: 10.1371/journal.pone. 0032601 PMID: 22389711; PubMed Central PMCID: PMC3289656.
9. Schwartz-Cornil I, Mertens PP, Contreras V, Hemati B, Pascale F, Breard E, et al. Bluetongue virus: virology, pathogenesis and immunity. Veterinary research. 2008; 39(5):46. Epub 2008/05/23. doi: 10. 1051/vetres:2008023 PMID: 18495078.
10. Jeggo MH, Wardley RC, Taylor WP. Role of neutralising antibody in passive immunity to bluetongue infection. Res Vet Sci. 1984; 36(1):81-6. PMID: 6324311.
11. Jeggo MH, Wardley RC, Brownlie J. A study of the role of cell-mediated immunity in bluetongue virus infection in sheep, using cellular adoptive transfer techniques. Immunology. 1984; 52(3):403-10. PMID: 6086501.
12. Stott JL, Osburn BI, Barber TL. The current status of research on an experimental inactivated bluetongue virus vaccine. Proceedings, annual meeting of the United States Animal Health Association. 1979;(83: ):55-62. Epub 1979/01/01. PMID: 233389.
13. Stott JL, Barber TL, Osburn BI. Immunologic response of sheep to inactivated and virulent bluetongue virus. Am J Vet Res. 1985; 46(5):1043-9. PMID: 2988376.
14. Takamatsu H, Jeggo MH. Cultivation of bluetongue virus-specific ovine T cells and their cross-reactivity with different serotype viruses. Immunology. 1989; 66(2):258-63. PMID: 2466772.
15. Janardhana V, Andrew ME, Lobato ZI, Coupar BE. The ovine cytotoxic T lymphocyte responses to bluetongue virus. Res Vet Sci. 1999; 67(3):213-21. PMID: 10607500.
16. Andrew M, Whiteley P, Janardhana V, Lobato Z, Gould A, Coupar B. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Veterinary immunology and immunopathology. 1995; 47(3-4):311-22. Epub 1995/08/01. PMID: 8571549.
17. Umeshappa CS, Singh KP, Pandey AB, Singh RP, Nanjundappa RH. Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep. Vaccine. 2010; 28(13):2522-31. Epub 2010/02/02. doi: 10.1016/j.vaccine.2010.01.039 PMID: 20117268.
18. Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S. Vaccines against bluetongue in Europe. Comparative immunology, microbiology and infectious diseases. 2008; 31(2-3):101-20. Epub 2007/09/04. doi: 10.1016/j.cimid.2007.07.006 PMID: 17765305.
19. Batten CA, Maan S, Shaw AE, Maan NS, Mertens PP. A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. Virus research. 2008; 137 (1):56-63. PMID: 18598726. doi: 10.1016/j.virusres.2008.05.016
20. MacLachlan NJ, Osburn BI, Stott JL, Ghalib HW. Orbivirus infection of the bovine fetus. Progress in clinical and biological research. 1985; 178:79-84. Epub 1985/01/01. PMID: 2989930.
21. Hamers C, Galleau S, Chery R, Blanchet M, Besancon L, Cariou C, et al. Use of inactivated bluetongue virus serotype 8 vaccine against virulent challenge in sheep and cattle. The Veterinary record. 2009; 165(13):369-73. Epub 2009/09/29. PMID: 19783850.
22. Szmaragd C, Wilson AJ, Carpenter S, Wood JL, Mellor PS, Gubbins S. The spread of bluetongue virus serotype 8 in Great Britain and its control by vaccination. PloS one. 2010; 5(2):e9353. Epub 2010/02/25. doi: 10.1371/journal.pone.0009353 PMID: 20179768; PubMed Central PMCID: PMC2825270.
23. Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, et al. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine. 2007; 25(4):672-8. Epub 2006/10/25. doi: 10.1016/j. vaccine.2006.08.025 PMID: 17059856.
24. Calvo-Pinilla E, Rodriguez-Calvo T, Sevilla N, Ortego J. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine. 2009; 28(2):437-45. Epub 2009/10/28. doi: 10.1016/j.vaccine.2009.10.027 PMID: 19857449.
25. Ma G, Eschbaumer M, Said A, Hoffmann B, Beer M, Osterrieder N. An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PloS one. 2012; 7(4):e34425. Epub 2012/04/19. doi: 10.1371/journal.pone. 0034425 PMID: 22511939; PubMed Central PMCID: PMC3325243.
26. Kochinger S, Renevey N, Hofmann MA, Zimmer G. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection. Veterinary research. 2014; 45:64. Epub 2014/06/15. doi: 10.1186/1297-9716-45-64 PMID: 24928313; PubMed Central PMCID: PMC4063687.
27. Wade-Evans AM, Romero CH, Mellor P, Takamatsu H, Anderson J, Thevasagayam J, et al. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology. 1996; 220(1):227-31. Epub 1996/06/01. doi: 10.1006/viro.1996.0306 PMID: 8659119.
28. Rojas JM, Rodriguez-Calvo T, Pena L, Sevilla N. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep. Vaccine. 2011; 29(40):6848-57. Epub 2011/08/03. doi: 10.1016/j.vaccine.2011.07.061 PMID: 21807057.
29. Bouet-Cararo C, Contreras V, Caruso A, Top S, Szelechowski M, Bergeron C, et al. Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep. PloS one. 2014; 9(11):e111605. Epub 2014/11/05. doi: 10.1371/journal.pone.0111605 PMID: 25364822; PubMed Central PMCID: PMC4218782.
30. Jones LD, Chuma T, Hails R, Williams T, Roy P. The non-structural proteins of bluetongue virus are a dominant source of cytotoxic T cell peptide determinants. The Journal of general virology. 1996; 77 (Pt 5):997-1003. PMID: 8609498.
31. Lobato ZI, Coupar BE, Gray CP, Lunt R, Andrew ME. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Veterinary immunology and immunopathology. 1997; 59(3-4):293-309. Epub 1998/02/27. PMID: 9477479.
32. White JR, Eaton BT. Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup. The Journal of general virology. 1990; 71 (Pt 6):1325-32. Epub 1990/06/01. doi: 10.1099/0022-1317-71-6-1325 PMID: 1693664.
33. van Rijn PA, Heutink RG, Boonstra J, Kramps HA, van Gennip RG. Sustained high-throughput polymerase chain reaction diagnostics during the European epidemic of Bluetongue virus serotype 8. Journal of veterinary diagnostic investigation: official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc. 2012; 24(3):469-78. Epub 2012/04/25. doi: 10.1177/1040638712440986 PMID: 22529113.
34. Calvo-Pinilla E, Rodriguez-Calvo T, Anguita J, Sevilla N, Ortego J. Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PloS one. 2009; 4(4): e5171. Epub 2009/04/10. doi: 10.1371/journal.pone.0005171 PMID: 19357779; PubMed Central PMCID: PMC2663843.
35. Rojas JM, Moreno H, Garcia A, Ramirez JC, Sevilla N, Martin V. Two replication-defective adenoviral vaccine vectors for the induction of immune responses to PPRV. Vaccine. 2014; 32(3):393-400. Epub 2013/11/26. doi: 10.1016/j.vaccine.2013.11.033 PMID: 24269622.
36. Sambrook J, Russell DW. Molecular cloning: a laboratory manual, 3rd ed. New York: ColdSpring Harbor Laboratory Press; 2001.
37. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994; 264(5167):1918-21. Epub 1994/06/24. PMID: 8009221.
38. Caporale M, Di Gialleonorado L, Janowicz A, Wilkie G, Shaw A, Savini G, et al. Virus and host factors affecting the clinical outcome of bluetongue virus infection. Journal of virology. 2014; 88(18):10399-411. Epub 2014/07/06. doi: 10.1128/JVI.01641-14 PMID: 24991012; PubMed Central PMCID: PMC4178883.
39. Toussaint JF, Sailleau C, Breard E, Zientara S, De Clercq K. Bluetongue virus detection by two realtime RT-qPCRs targeting two different genomic segments. Journal of virological methods. 2007; 140 (1-2):115-23. Epub 2007/01/02. doi: 10.1016/j.jviromet.2006.11.007 PMID: 17196266.
40. Matsuo E, Celma CC, Boyce M, Viarouge C, Sailleau C, Dubois E, et al. Generation of replicationdefective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge. Journal of virology. 2011; 85(19):10213-21. Epub 2011/07/29. doi: 10.1128/JVI.05412-11 PMID: 21795358; PubMed Central PMCID: PMC3196398.
41. Maclachlan NJ, Henderson C, Schwartz-Cornil I, Zientara S. The immune response of ruminant livestock to bluetongue virus: from type I interferon to antibody. Virus research. 2014; 182:71-7. Epub 2013/10/15. doi: 10.1016/j.virusres.2013.09.040 PMID: 24120757.
42. Quinn KM, Zak DE, Costa A, Yamamoto A, Kastenmuller K, Hill BJ, et al. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. The Journal of clinical investigation. 2015; 125(3):1129-46. Epub 2015/02/03. doi: 10.1172/JCI78280 PMID: 25642773; PubMed Central PMCID: PMC4362254.
43. Rojas JM, Moreno H, Valcarcel F, Pena L, Sevilla N, Martin V. Vaccination with recombinant adenoviruses expressing the peste des petits ruminants virus F or H proteins overcomes viral immunosuppression and induces protective immunity against PPRV challenge in sheep. PloS one. 2014; 9(7): e101226. Epub 2014/07/12. doi: 10.1371/journal.pone.0101226 PMID: 25013961; PubMed Central PMCID: PMC4094465.
44. Inumaru S, Roy P. Production and characterization of the neutralization antigen VP2 of bluetongue virus serotype 10 using a baculovirus expression vector. Virology. 1987; 157(2):472-9. Epub 1987/04/01 PMID: 3029984.
45. Anderson J, Breard E, Lovgren Bengtsson K, Gronvik KO, Zientara S, Valarcher JF, et al. Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals. Clinical and vaccine immunology: CVI. 2014; 21(3):443-52. Epub 2014/01/24. doi: 10.1128/CVI.00776-13 PMID: 24451327; PubMed Central PMCID: PMC3957662.
46. Huismans H, van der Walt NT, Cloete M, Erasmus BJ. Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep. Virology. 1987; 157(1):172-9. Epub 1987/03/01. PMID: 3029956.
47. Zhang X, Boyce M, Bhattacharya B, Zhang X, Schein S, Roy P, et al. Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(14):6292-7. Epub 2010/03/25. doi: 10.1073/pnas.0913403107 PMID: 20332209; PubMed Central PMCID: PMC2852009.
48. Jabbar TK, Calvo-Pinilla E, Mateos F, Gubbins S, Bin-Tarif A, Bachanek-Bankowska K, et al. Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. PloS one. 2013; 8(4):e60574. Epub 2013/04/18. doi: 10.1371/journal.pone.0060574 PMID: 23593251; PubMed Central PMCID: PMC3625202.
49. Frenz T, Waibler Z, Hofmann J, Hamdorf M, Lantermann M, Reizis B, et al. Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankarainduced T-cell expansion. European journal of immunology. 2010; 40(10):2769-77. Epub 2010/09/08. doi: 10.1002/eji.201040453 PMID: 20821729.
50. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nature immunology. 2003; 4(10):1009-15. Epub 2003/09/23. doi: 10.1038/ni978 PMID: 14502286.
51. Kastenmuller K, Wille-Reece U, Lindsay RW, Trager LR, Darrah PA, Flynn BJ, et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. The Journal of clinical investigation. 2011; 121(5):1782-96. Epub 2011/05/05. doi: 10.1172/JCI45416 PMID: 21540549; PubMed Central PMCID: PMC3083762.
52. Cui W, Kaech SM. Generation of effector CD8+ T cells and their conversion to memory T cells. Immunological reviews. 2010; 236:151-66. Epub 2010/07/20. doi: 10.1111/j.1600-065X.2010.00926.x PMID: 20636815; PubMed Central PMCID: PMC4380273.